Year Founded
2017
Ownership
Private
Employees
~10
Stage
Phase 1
Modalities
Autologous cell therapyProtein therapeutics

Rise Therapeutics General Information

Multiple Phase 1 clinical trials ongoing for ulcerative colitis, rheumatoid arthritis, type 1 diabetes, and cancer. Recently received FDA IND clearance for R-5780 in cancer. Completed dose escalation for R-3750 and R-2487 trials.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

R-5780
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Rise Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Rise Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Rise Therapeutics's complete valuation and funding history, request access »

Rise Therapeutics Investors

NIDDK/NIH through Commercial Readiness Pilot (CRP) Program SBIR award
Investor Type: Venture Capital
Holding: Minority